TCGA-GU-A42P-01A-11R-A23W-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 10.90670171
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.370
- G2M_CHECKPOINT+0.300
- PROTEIN_SECRETION+0.280
- SPERMATOGENESIS+0.230
- CHOLESTEROL_HOMEOSTASIS+0.160
- MITOTIC_SPINDLE+0.160
- FATTY_ACID_METABOLISM+0.120
- PEROXISOME+0.120
- DNA_REPAIR+0.110
- BILE_ACID_METABOLISM+0.060
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.590
- INTERFERON_GAMMA_RESPONSE-0.580
- INTERFERON_ALPHA_RESPONSE-0.560
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.550
- TNFA_SIGNALING_VIA_NFKB-0.540
- INFLAMMATORY_RESPONSE-0.470
- ANGIOGENESIS-0.460
- IL6_JAK_STAT3_SIGNALING-0.440
- KRAS_SIGNALING_UP-0.410
- IL2_STAT5_SIGNALING-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OR-A5K4-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.922 |
| 2 | TCGA-GV-A3JW-01A-11R-A20F-07 | — | — | 0.915 |
| 3 | TCGA-G2-A3VY-01A-11R-A22U-07 | — | — | 0.908 |
| 4 | TCGA-DK-AA76-01A-11R-A39I-07 | — | — | 0.907 |
| 5 | SRR650147 | — | — | 0.894 |
| 6 | TCGA-GV-A3QI-01A-11R-A220-07 | — | — | 0.893 |
| 7 | BS_HTEPAKCM | medulloblastoma | — | 0.889 |
| 8 | TCGA-E7-A5KE-01A-11R-A28M-07 | — | — | 0.889 |
| 9 | TCGA-ZF-A9RL-01A-11R-A38B-07 | — | — | 0.885 |
| 10 | BS_5PJCHF6V | medulloblastoma | — | 0.885 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |